These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

170 related items for PubMed ID: 6540852

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Selective toxicity of a new lipophilic antifolate, BW301U, for methotrexate-resistant cells with reduced drug uptake.
    Taylor IW, Slowiaczek P, Friedlander ML, Tattersall MH.
    Cancer Res; 1985 Mar; 45(3):978-82. PubMed ID: 3971388
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Expression of variant dihydrofolate reductase with decreased binding affinity to antifolates in MOLT-3 human leukemia cell lines resistant to trimetrexate.
    Miyachi H, Takemura Y, Kobayashi H, Ando Y.
    Cancer Lett; 1995 Jan 06; 88(1):93-9. PubMed ID: 7850779
    [Abstract] [Full Text] [Related]

  • 8. Novel 6,5-fused ring heterocyclic antifolates: biochemical and biological characterization.
    McGuire JJ, Bergoltz VV, Heitzman KJ, Haile WH, Russell CA, Bolanowska WE, Kotake Y, Haneda T, Nomura H.
    Cancer Res; 1994 May 15; 54(10):2673-9. PubMed ID: 8168096
    [Abstract] [Full Text] [Related]

  • 9. Kinetic and molecular properties of the dihydrofolate reductase from pyrimethamine-sensitive and pyrimethamine-resistant clones of the human malaria parasite Plasmodium falciparum.
    Chen GX, Mueller C, Wendlinger M, Zolg JW.
    Mol Pharmacol; 1987 Apr 15; 31(4):430-7. PubMed ID: 3553892
    [Abstract] [Full Text] [Related]

  • 10. Studies concerned with overcoming resistance to methotrexate: a comparison of the effects of methotrexate and 2,4-diamino-5-(3',4'-dichlorophenyl)-6-methylpyrimidine (BW50197) on the colony forming ability of L5178Y cells.
    Hill BT, Goldie JH, Price LA.
    Br J Cancer; 1973 Sep 15; 28(3):263-8. PubMed ID: 4743908
    [Abstract] [Full Text] [Related]

  • 11. Molecular mechanisms of resistance to antifolates, a review.
    Banerjee D, Ercikan-Abali E, Waltham M, Schnieders B, Hochhauser D, Li WW, Fan J, Gorlick R, Goker E, Bertino JR.
    Acta Biochim Pol; 1995 Sep 15; 42(4):457-64. PubMed ID: 8852336
    [Abstract] [Full Text] [Related]

  • 12. Characterization of the coexisting multiple mechanisms of methotrexate resistance in mouse 3T6 R50 fibroblasts.
    Assaraf YG, Feder JN, Sharma RC, Wright JE, Rosowsky A, Shane B, Schimke RT.
    J Biol Chem; 1992 Mar 25; 267(9):5776-84. PubMed ID: 1372892
    [Abstract] [Full Text] [Related]

  • 13. Metabolic inhibition by a new antifolate, 2,4-diamino-6-(2,5-dimethoxybenzyl)-5-methyl-pyrido[2,3-d]pyrimidine (BW3O1U), an effective inhibitor of human lymphoid and dihydrofolate reductase-overproducing mouse cell lines.
    Sedwick WD, Hamrell M, Brown OE, Laszlo J.
    Mol Pharmacol; 1982 Nov 25; 22(3):766-70. PubMed ID: 7155133
    [Abstract] [Full Text] [Related]

  • 14. A phenotype conferring selective resistance to lipophilic antifolates in Chinese hamster ovary cells.
    Sharma RC, Assaraf YG, Schimke RT.
    Cancer Res; 1991 Jun 01; 51(11):2949-59. PubMed ID: 1674447
    [Abstract] [Full Text] [Related]

  • 15. Biochemical and biological studies on 2-desamino-2-methylaminopterin, an antifolate the polyglutamates of which are more potent than the monoglutamate against three key enzymes of folate metabolism.
    Rosowsky A, Galivan J, Beardsley GP, Bader H, O'Connor BM, Russello O, Moroson BA, DeYarman MT, Kerwar SS, Freisheim JH.
    Cancer Res; 1992 Apr 15; 52(8):2148-55. PubMed ID: 1313737
    [Abstract] [Full Text] [Related]

  • 16. Dihydrofolate reductase activity in adriamycin and methotrexate sensitive and resistant P388 leukemia cells.
    Mandelbaum-Shavit F, Ramu A.
    Cell Biol Int Rep; 1987 May 15; 11(5):389-96. PubMed ID: 3607890
    [Abstract] [Full Text] [Related]

  • 17. Loss of folylpoly-gamma-glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation-dependent novel antifolates in multiple human leukemia sublines.
    Liani E, Rothem L, Bunni MA, Smith CA, Jansen G, Assaraf YG.
    Int J Cancer; 2003 Feb 20; 103(5):587-99. PubMed ID: 12494465
    [Abstract] [Full Text] [Related]

  • 18. Drosophila dihydrofolate reductase mutations confer antifolate resistance to mammalian cells.
    Affleck JG, Al-Batayneh KM, Neumann K, Cole SP, Walker VK.
    Eur J Pharmacol; 2006 Jan 04; 529(1-3):71-8. PubMed ID: 16325803
    [Abstract] [Full Text] [Related]

  • 19. Multiple mechanisms of resistance to polyglutamatable and lipophilic antifolates in mammalian cells: role of increased folylpolyglutamylation, expanded folate pools, and intralysosomal drug sequestration.
    Jansen G, Barr H, Kathmann I, Bunni MA, Priest DG, Noordhuis P, Peters GJ, Assaraf YG.
    Mol Pharmacol; 1999 Apr 04; 55(4):761-9. PubMed ID: 10101035
    [Abstract] [Full Text] [Related]

  • 20. Biochemical and genetic tests for inhibitors of Leishmania pteridine pathways.
    Hardy LW, Matthews W, Nare B, Beverley SM.
    Exp Parasitol; 1997 Nov 04; 87(3):157-69. PubMed ID: 9371081
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.